Abstract
Objective:
To analyze the titers of the IgG and IgM antibodies against human herpesvirus 6A/B (HHV-6A/B) in multiple sclerosis (MS) patients treated with different disease modified therapies (DMTs) along two-years of follow-up.
Methods:
We collected 2163 serum samples from 596 MS; for 301 MS patients a 2-years follow-up was performed. Serum samples of 337 healthy controls were also analyzed. Anti-HHV-6A/B IgG and IgM were analyzed by ELISA (Panbio).
Results:
We found that 129/187 (69.0%) MS patients with a decrease of the anti-HHV-6A/B IgG titers after 2-years with DMTs were free of relapses and progression vs. 46/113 (40.7%) of MS patients with an increase of the anti-HHV-6A/B IgG titers (p = 0.0000015); the higher significance was found for natalizumab. Furthermore, we found that anti-HHV-6A/B IgG titers reached their highest value two weeks before the relapse (p = 0.0142), while the anti-HHV-6A/B IgM titers reached their highest value one month before the relapse (p = 0.0344).
Conclusion:
The measurement of the anti-HHV-6A/B IgG titers could be a good biomarker of clinical response to the different DMTs. The increase of the anti-HHV-6A/B IgG and IgM titers predicts the upcoming clinical relapses. However, further longitudinal studies are needed to validate these results.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antibodies, Neutralizing / blood
-
Antibodies, Neutralizing / immunology
-
Antibodies, Viral / immunology*
-
Biomarkers / blood
-
Disease Progression
-
Female
-
Herpesvirus 6, Human / immunology*
-
Humans
-
Immunoglobulin G / blood*
-
Immunoglobulin G / immunology
-
Immunoglobulin M / blood*
-
Immunoglobulin M / immunology
-
Immunologic Factors / therapeutic use
-
Interferon-beta / immunology
-
Male
-
Multiple Sclerosis / blood
-
Multiple Sclerosis / genetics
-
Multiple Sclerosis / therapy*
-
Natalizumab / therapeutic use
-
Recurrence
Substances
-
Antibodies, Neutralizing
-
Antibodies, Viral
-
Biomarkers
-
Immunoglobulin G
-
Immunoglobulin M
-
Immunologic Factors
-
Natalizumab
-
Interferon-beta
Grants and funding
Roberto Alvarez-Lafuente is recipient of a research contract of the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (Feder) (CP07/00273). Arias-Leal and Garcia-Martinez are recipients of a technician contract from “REEM: Red Española de Esclerosis Múltiple” (RETICS-REEM RD12/0032/0001;
www.reem.es). This work was financially supported by grants from the Instituto de Salud Carlos III-Fondo Europeo de Desarrollo Regional (Feder) (FIS PI12/02349), “Fundación Mutua Madrileña”, and “Fundación LAIR”. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.